Pharmx Technologies Ltd Confirms Sigma Healthcare to Reach 10% Stake
Sigma Healthcare completes move to full 10% stake in Pharmx
Pharmx Technologies (ASX: PHX) has confirmed that Sigma Healthcare Limited (Sigma) will move to a full 10% shareholding, completing the equity component of the multi-year strategic alliance first announced on 23 February 2026.
Sigma’s initial subscription of 59,950,679 shares is complete, giving it approximately 9.1% of Pharmx on a post-issue basis. To reach the intended level, Pharmx will issue an additional 6,661,187 ordinary shares at $0.145 per share, taking Sigma to a full 10% of issued capital as originally contemplated under the Strategic Alliance Agreement.
Importantly, no other term of the alliance changes as a result of this step.
The final step confirming the strategic alliance
The first was Sigma’s initial subscription, which lifted its holding to roughly 9.1%. The second is the top-up now agreed, designed to close the gap to the full 10% target.
The additional shares will be issued at the same price per share ($0.145) as Sigma’s original subscription under the Agreement. The issuance falls within Pharmx’s existing placement capacity under Listing Rule 7.1.
For investors, a major, established healthcare player cementing a full 10% stake signals conviction in the Pharmx platform.
| Transaction stage | Shares | Price | Resulting holding | Status |
|---|---|---|---|---|
| Initial subscription | 59,950,679 | $0.145 | ~9.1% | Complete |
| Additional top-up | 6,661,187 | $0.145 | 10% (combined) | To be issued |
The announcement does not disclose a total dollar value or a completion date for the top-up. Under the original agreement, Sigma also holds a seat on the Pharmx Board.
Why a pharmacy ordering platform matters
Pharmx describes itself as ANZ’s leading pharmacy ordering platform, providing technology infrastructure for ordering and inventory management across the pharmacy supply chain. In practical terms, the platform links pharmacies with suppliers and technology vendors, streamlining how orders are placed and stock is managed.
According to the company, the platform:
-
Facilitates approximately $20 billion in transactions annually
-
Connects the largest network of pharmacies, suppliers and technology vendors
-
Offers ordering, eInvoicing and analytics solutions
Sigma is a major participant in the pharmacy sector. A strategic shareholder of that profile aligning with the platform is commercially logical, deepening ties across the pharmacy supply chain and reinforcing the network at the centre of Pharmx’s model.
What the alliance means for the investment case
The core takeaway is the presence of a cornerstone strategic shareholder now fully committed at the intended level. Key points for investors include:
-
A full 10% strategic holding now secured as originally intended
-
Board representation that aligns a major industry partner with shareholder interests
-
A market position exposed to growth drivers such as population growth, demographic shifts and regulatory change
Pharmx has stated its focus on expanding its addressable market by leveraging its network, proprietary pharma-tech and advanced data capabilities across Australia and New Zealand.
Announcement authorisation
The completion update was authorised for release by the Board of Pharmx Technologies Limited. For further information, contact Tom Culver, Chief Executive Officer.
Next steps
The additional 6,661,187 ordinary shares are to be issued within Pharmx’s existing placement capacity under Listing Rule 7.1, taking Sigma’s holding to a full 10%. No other term of the Strategic Alliance Agreement changes, and no specific completion date has been disclosed.
When big ASX news breaks, our subscribers know first
Don’t Miss the Next Healthcare Tech Move on ASX
Big News Blast delivers FREE breaking ASX healthcare and tech news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at StockWire X to make sure you never miss the moment market-moving news drops.